New drug combo aims to outsmart Platinum-Resistant ovarian cancer
NCT ID NCT05198804
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, so while promising, it is not yet proven as a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Azenosertib (ZN-c3) and niraparib
What this could lead to
If successful, this could provide a new treatment option for women with ovarian cancer that no longer responds to platinum-based chemotherapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 117 participants, so results may not apply to all patients. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Oncology Associates (Wilmot HOPE) - USOR
Tucson, Arizona, 85711, United States
-
Centre Georges François Leclerc
Dijon, France
-
Centre Hospitalier Lyon Sud
Saint-Genis-Laval, France
-
Centre Oscar Lambret
Lille, France
-
EDOG - Institut Claudius Regaud
Toulouse, France
-
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
-
Institut Gustave Roussy
Villejuif, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center, Gynecologic Oncology Center
Texas City, Texas, 77030, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Optimum Clinical Research Group- Women's Oncology
Albuquerque, New Mexico, 87109, United States
-
Rocky Mountain Cancer Centers
Aurora, Colorado, 80012, United States
-
Rutgers New Jersey Medical School
Newark, New Jersey, 07103, United States
-
Spectrum Health System
Grand Rapids, Michigan, 49503, United States
-
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas, 76104, United States
-
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York, 10011, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, 97401, United States
-
Women and Infants Hospital of Rhode Island
Providence, Rhode Island, 02905, United States